Please assess the completion status of the following clinical trial:

Trial Title: Enhancing Memory Consolidation in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English speaking~* non-smoker~* between the ages of 60 to 75, without major medical problems~* have a regular sleep wake schedule, defined as obtaining 6-9 hours of sleep per night, with a habitual bedtime before 2am and a habitual wake time before 10am~* must have experience with Ambien to participate in the study.~Exclusion Criteria:~* have a sleeping disorder (reported or detected on questionnaires)~* have any personal or immediate family history of diagnosed mental disorders~* have any personal history of head injury with loss of consciousness greater than 2 minutes or seizures~* have a history of substance dependence~* currently use any medications that could affect sleep and/or thought processes~* have any cardiac, respiratory or other medical condition which may affect cerebral metabolism~* have dementia~* have non-correctable vision and hearing impairments, due to the nature of the stimulus and its presentation, will also be excluded.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Nap/5mg Zolpidem (Type: ACTIVE_COMPARATOR): The research involves oral administration of zolpidem (ZOL, 5mg) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced. During the experimental phase, each drug condition will include one day in the sleep lab, two encoding test sessions, and one retrieval test session. Multiple subjects will be in the experimental phase concurrently, and multiple subjects will be tested on each day.
- Nap/Placebo (Type: PLACEBO_COMPARATOR): The research involves oral administration of zolpidem (ZOL, 5mg) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced. During the experimental phase, each drug condition will include one day in the sleep lab, two encoding test sessions, and one retrieval test session. Multiple subjects will be in the experimental phase concurrently, and multiple subjects will be tested on each day.

Based on this trial design, predict the completion outcome and termination type (if applicable).